Evidence map›Paper›PMID 25493596›Full record

Trial reportAIDS (London, England)2014

Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.

Moses R Kamya, James Kapisi, Victor Bigira, Tamara D Clark, Stephen Kinara, Florence Mwangwa, Mary K Muhindo, Abel Kakuru, Francesca T Aweeka, Liusheng Huang and 5 more

2 registry-linked trialsOpen access · greenAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 5 pooled it
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00948896 phase3completednot on this map

A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2014Enrolled600ConditionsMalariaArmstrimethoprim-sulfamethoxazole (TS, TMP/SMX), sulfadoxine-pyrimethamine (SP), dihydroartemisinin-piperaquine (DP)
NCT04844099 phase3completednot on this mapstarted 2021, after this paper: background citation

Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)

TypeinterventionalSponsorLiverpool School of Tropical MedicineRan2021 to 2023Enrolled723ConditionsSickle Cell Anemia in Children, MalariaArmsDihydroartemisinin Piperaquine
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Intermittent preventive treatment for malaria in infants.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Intermittent preventive treatment for malaria in infants.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Article
  20. The feasibility of an automated eye-tracking-modified Fagan test of memory for human faces in younger Ugandan HIV-exposed children.Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Moses R KamyaaDepartment of Medicine, Makerere University College of Health Sciences bInfectious Diseases Research Collaboration, Kampala, Uganda cDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA dDepartment of Pediatrics, Makerere University College of Health Sciences, Kampala, Uganda.
James Kapisi
Victor Bigira
Tamara D Clark
Stephen Kinara
Florence Mwangwa
Mary K Muhindo
Abel Kakuru
Francesca T Aweeka
Liusheng Huang
Prasanna Jagannathan
Jane Achan
Diane V Havlir
Philip J Rosenthal
Grant Dorsey
Infectious Diseases Research Collaboration · UGSan Francisco General Hospital · USUniversity of California, San Francisco · USMakerere University · UG

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
The immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6M
Immunologic Consequences of Highly Effective Antimalarial ChemopreventionK23AI100949 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAGANNATHAN, PRASANNA · 2012 to 2016
$657k
NIAID NIH HHS K23 AI100949NIAID NIH HHS P30 AI027763NIAID NIH HHS UM1 AI069496NICHD NIH HHS HD059454NICHD NIH HHS P01 HD059454
6 · The paper itself

Abstract

objectiveTrimethoprim-sulfamethoxazole prophylaxis is recommended for HIV-exposed infants until breastfeeding ends and HIV infection has been excluded. Extending prophylaxis with a focus on preventing malaria may be beneficial in high transmission areas. We investigated three regimens for the prevention of malaria in young HIV-exposed children.

designAn open-label, randomized controlled trial.

settingTororo, Uganda, a rural area with intense, year-round, malaria transmission.

participantsTwo hundred infants aged 4-5 months enrolled and 186 randomized after cessation of breastfeeding and confirmed to be HIV uninfected (median 10 months of age).

interventionNo chemoprevention, monthly sulfadoxine-pyrimethamine, daily trimethoprim-sulfamethoxazole or monthly dihydroartemisinin-piperaquine given from randomization to 24 months of age.

main outcome measuresThe primary outcome was the incidence of malaria during the intervention period. Secondary outcomes included the incidence of hospitalization, diarrhoeal illness, or respiratory tract infection; prevalence of anaemia and asymptomatic parasitemia; measures of safety; and incidence of malaria over 1 year after the intervention was stopped.

resultsDuring the intervention, the incidence of malaria in the no chemoprevention group was 6.28 episodes per person-year at risk. Protective efficacy was 69% [95% confidence interval (95% CI) 53-80, P < 0.001] for dihydroartemisinin-piperaquine, 49% (95% CI 23-66, P = 0.001) for trimethoprim-sulfamethoxazole and 9% for sulfadoxine-pyrimethamine (95% CI -35 to 38, P = 0.65). There were no significant differences in any secondary outcomes, with the exception of a lower prevalence of asymptomatic parasitemia in the dihydroartemisinin-piperaquine arm.

conclusionMonthly chemoprevention with dihydroartemisinin-piperaquine was well tolerated and associated with a significant reduction in malaria in young HIV-exposed children.

Indexed as

AntimalarialsArtemisininsChemopreventionChild, PreschoolCohort StudiesDrug CombinationsFemaleHumansInfantMalariaMalePiperazinesPyrimethamineQuinolinesSulfadoxineTreatment OutcomeAntimalarialsArtemisininsartenimolDrug Combinationsfanasil, pyrimethamine drug combinationpiperaquinePiperazinesPyrimethamineQuinolinesSulfadoxineTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID25493596
PMCPMC4487368
OpenAlexW2334186750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.